Scarica l'app Stockscreener
166.29
0.03%
0.05
Dopo l'orario di chiusura:
166.18
-0.11
-0.07%
Jazz Pharmaceuticals Plc Borsa (JAZZ) Ultime notizie
LSV Asset Management Sells 41,884 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026 - GlobeNewswire Inc.
Is the Options Market Predicting a Spike in Jazz Pharmaceuticals Stock? - Yahoo Finance
Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026 - PR Newswire UK
Essex Investment Management Co. LLC Invests $2.70 Million in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals (JAZZ) Valuation After HERIZON GEA Trial Upside And Planned 2026 sBLA Filing - simplywall.st
Renaissance Group LLC Sells 7,254 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Lupin Receives Tentative Approval from U.S. FDA for Calcium, Magnesium, Potassium, and Sodium Oxybates Oral SolutionLupin | Press Release - lupin.com
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
How HERIZON-GEA’s First-Line GEA Data And sBLA Plan At Jazz Pharmaceuticals (JAZZ) Has Changed Its Investment Story - simplywall.st
The Best Biotech Stocks to Buy - Morningstar
Allianz Asset Management GmbH Purchases 30,537 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Zacks Research Brokers Lower Earnings Estimates for JAZZ - MarketBeat
New Drugs Take Center Stage as Biogen Heads Into Q4 Earnings - Yahoo Finance
What is Zacks Research's Estimate for JAZZ Q1 Earnings? - MarketBeat
Truist Securities Raises Jazz Pharmaceuticals (JAZZ) Price Target After HERIZON-GEA Trial - Insider Monkey
Strs Ohio Sells 14,393 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals plc (JAZZ): Investor Outlook with a 32% Potential Upside and Strong Buy Ratings - DirectorsTalk Interviews
What is the target price for Jazz Pharmaceuticals plc stockMarket Risk Analysis & High Win Rate Trade Tips - baoquankhu1.vn
Autistic Disorder Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Jazz Pharma, Axial Therapeutics, Eli Lilly and Company, Scioto Bioscienc - Barchart.com
Autistic Disorder Pipeline 2025: Therapies Under - openPR.com
Top Investors’ Stock Portfolio: 10 Mid-cap Stocks To Buy - Insider Monkey
The Truth About Jazz Pharmaceuticals: Why Wall Street Suddenly Can’t Shut Up - AD HOC NEWS
Is Jazz Pharmaceuticals (JAZZ) Offering An Opportunity After Recent Share Price Pullback - Yahoo Finance
Is Jazz Pharmaceuticals (JAZZ) Offering Opportunity After A 32% One Year Share Price Gain - simplywall.st
These 4 Measures Indicate That Jazz Pharmaceuticals (NASDAQ:JAZZ) Is Using Debt Reasonably Well - 富途牛牛
Jazz Pharmaceuticals PLC $JAZZ Shares Bought by Great Lakes Advisors LLC - MarketBeat
Lewy Body Dementia Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Jazz Pharma, Allergan, Noven Pharma, Takeda Pharma, Eli Lilly, Mallinckrodt - Barchart.com
Mitsubishi UFJ Trust & Banking Corp Raises Stake in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Aug Weekly: Is ADPT a good ESG investmentStop Loss & Stock Portfolio Risk Management - baoquankhu1.vn
Harmony Biosciences' Sales and Profits Have Soared. Why Hasn't Its Stock Followed? - Finviz
Auvelity Continues to Aid AXSM's Top Line: More Upside in 2026? - Yahoo Finance
Jazz Pharmaceuticals (JAZZ) Stock Analysis: Unpacking A Promising 28% Upside Potential - DirectorsTalk Interviews
How Boehringer Ingelheim Oncology Collaboration Could Shape Jazz Pharmaceuticals' (JAZZ) Dual HER2 Strategy - simplywall.st
Universal Beteiligungs und Servicegesellschaft mbH Cuts Position in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Assessing Jazz Pharmaceuticals (JAZZ) Valuation After New Boehringer Ingelheim Oncology Collaboration - simplywall.st
Aug Update: Should I invest in Kaltura Inc before earningsEarnings Miss & Intraday High Probability Alerts - baoquankhu1.vn
Dip Buying: Why is Jazz Pharmaceuticals plc stock going upEarnings Risk Report & Stepwise Trade Signal Implementation - baoquankhu1.vn
Acute Myeloid Leukemia Market Forecast to 2034: 7MM Opportunity, Strong CAGR, 43,500 Annual Cases, and Pipeline-Driven Growth | DelveInsight - Barchart.com
Lmcg Investments LLC Trims Stake in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Aug Mood: Will Jazz Pharmaceuticals plc benefit from green energy policiesTrade Exit Report & Community Consensus Stock Picks - baoquankhu1.vn
Jazz Pharmaceuticals (JAZZ) Is Up 5.1% After Monetizing FDA Voucher And Expanding Oncology Collaboration - Yahoo Finance
Is Jazz (JAZZ) Quietly Recasting Its Oncology Strategy Through HER2 Partnerships And Voucher Monetization? - simplywall.st
New York State Teachers Retirement System Sells 9,223 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug - MSN
Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Recent Share Price Momentum - simplywall.st
JPM26: Jazz sells PRV for $200m, targets deals in 2026 - Pharmaceutical Technology
JAZZJazz Pharmaceuticals Plc Latest Stock News & Market Updates - Stock Titan
Jazz Sells Priority Review Voucher for $200M as Program’s Renewal Languishes in Senate - BioSpace
Jazz Pharmaceuticals stock rating reiterated at Outperform by RBC Capital - Investing.com Nigeria
Jazz Pharmaceuticals Soars with Promising HERIZON-GEA-01 Results - timothysykes.com
Jazz sells priority review voucher for $200 million - First Word Pharma
JAZZ: Sharpened rare disease focus, record growth, and pivotal zanidatamab results drive future milestones - TradingView — Track All Markets
JAZZ: Rare disease focus, record revenues, and zanidatamab's breakthrough in GEA drive future growth - TradingView — Track All Markets
JAZZ: Refined rare disease focus, strong 2025 results, and new launches drive future growth - TradingView
Baird reiterates Underperform rating on Jazz Pharmaceuticals stock at $209 By Investing.com - Investing.com Nigeria
Jazz Pharmaceuticals PLC $JAZZ Holdings Lessened by Polaris Capital Management LLC - MarketBeat
Jazz Pharmaceuticals price target raised to $235 from $210 at Needham - Yahoo Finance
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):